IOVANCE BIOTHERAPEUTICS, INC. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $373.37 million as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Investments › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2023-02-28
- 2022-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $373.37M.
- 2022-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $329.23M.
- 2022-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $412.25M.
- 2022-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $491.55M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2022-12-31 | $373.37M 10-K · filed 2023-02-28 |
| 2022-09-30 | $329.23M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $412.25M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $491.55M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $579.62M 10-K · filed 2022-02-24 |
| 2021-09-30 | $596.11M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $619.86M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $472.11M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |